n (%) | |
---|---|
Timing of primary CMV test (days of life) (n=86) | |
0–2 | 57 (66) |
3–6 | 21 (24) |
7–13 | 3 (3) |
14–20 | 5 (6) |
Type of primary CMV test (n=86) | |
PCR | 31 (36) |
Virus isolation | 31 (36) |
DEAFF | 21 (24) |
IgM (confirmed by PCR on neonatal dried blood spot) | 2 (2) |
Histology | 1 (1) |
Likely indication for CMV testing (n=85) | |
Neonatal symptoms compatible with CMV (see below) | 64 (75) |
Maternal/antenatal indication | 11 (13) |
Other* | 8 (9) |
No clear indication | 2 (2) |
Neonatal symptoms and signs compatible with CMV (n=85) | |
No | 21 (25) |
Yes, without neurological signs | 30 (35) |
Yes, with neurological signs | 34 (40) |
Systemic (n=85) | |
Hepatomegaly | 36 (42) |
Splenomegaly | 33 (39) |
Petechiae, purpura | 37 (44) |
Thrombocytopenia | 50 (59) |
Visual (n=79) | |
Chorioretinitis | 1 (1) |
Neurological (n=85) | |
Seizures | 3 (4) |
Intracranial calcification | 16 (19) |
Microcephaly (<3rd percentile)† | 26 (31) |
Small for gestational age (<3rd percentile) (n=85) | |
No | 58 (68) |
Yes | 27 (32) |
↵* Other reasons included severe prematurity (<32 weeks, n=2, one with a symptomatic twin), other neonatal symptoms (n=2), small head (although ≥3rd centile, n=2) and HIV-infected mother (n=2).
↵† 16 infants were microcephalic and small for gestational age.
DEAFF, detection of early antigen fluorescent foci. The primary CMV test was the first available positive test.